ClinicalTrials.gg
RecruitingNCT06619860Updated Jun 1, 2026

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 2 interventional study of VX-993 and Pregabalin in Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 47 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Planned enrollment
21st of 261
300 · median 40
Started
2024
with 17 others
Phase 2
78 of 291
5 open now
Primary completion
2027-03
later than 24 of 60 live
Registered
260th of 291
by date

Among the 291 studies in Neuralgia with a site in United States, this one is the 21st largest by planned enrollment of the 261 interventional ones that give a count, is one of 18 that started in 2024, is one of 78 in phase 2, reaches primary completion later than 24 of the 60 other live ones, and was the 260th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of diabetes mellitus type 1 or type 2 with

    • Glycosylated (HbA1c) less than or equal to (≤) 9% and
    • Presence of bilateral pain in lower extremities due to DPN (defined as a symmetric, length-dependent sensory or sensorimotor polyneuropathy) for at least 1 year

Key Exclusion Criteria:

  • Painful neuropathy other than DPN
  • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
  • History of a clinical atherosclerotic event, such as myocardial infarction or stroke, within the past 12 months

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    VX-993

    Participants will be randomized to receive multiple doses of different dose levels of VX-993.

    Drug: VX-993 · Drug: Placebo (matched to pregabalin)

  • Active comparator
    Pregabalin

    Participants will be randomized to receive Pregabalin.

    Drug: Pregabalin · Drug: Placebo (matched to VX-993)

Interventions

  • DrugVX-993

    Tablets for oral administration.

  • Capsules for oral administration.

  • DrugPlacebo (matched to pregabalin)

    Placebo matched to pregabalin for oral administration.

  • DrugPlacebo (matched to VX-993)

    Placebo matched to VX-993 for oral administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12

    Time frame: From Baseline up to Week 12

Secondary outcomes

  1. Proportion of Participants with Greater than or Equal to (≥) 30 Percent (%) Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12

    Time frame: From Baseline up to Week 12

  2. Proportion of Participants with ≥50% Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12

    Time frame: From Baseline up to Week 12

  3. Proportion of Participants with ≥70% Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12

    Time frame: From Baseline up to Week 12

  4. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 16

07

Study locations

22 of 47 sites recruiting
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
    Completed

    Not enrolling at this site — choose another above.

  • Trovare Clinical Research - Bakersfield CA
    Bakersfield, California 93301, United States
    Completed

    Not enrolling at this site — choose another above.

  • Eximia Research - San Diego
    La Mesa, California 91942, United States
    Completed

    Not enrolling at this site — choose another above.

  • Paradigm Clincial Research Centers, LLC., Wheat Ridge
    Wheat Ridge, Colorado 80033, United States
    Completed

    Not enrolling at this site — choose another above.

  • Accel Research - Deland
    DeLand, Florida 32720, United States
    Completed

    Not enrolling at this site — choose another above.

  • AMR Fort Myers (The Clinical Study Center)
    Fort Myers, Florida 33912, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research - Hallandale Beach
    Hallandale, Florida 33009, United States
    Completed

    Not enrolling at this site — choose another above.

  • Health Awareness, Inc., Jupiter
    Jupiter, Florida 33458, United States
    Completed

    Not enrolling at this site — choose another above.

  • Suncoast Research Associates - Miami
    Miami, Florida 33172, United States
    Completed

    Not enrolling at this site — choose another above.

  • Innovation Medical Research Center - Palmetto
    Palmetto Bay, Florida 33157, United States
    Completed

    Not enrolling at this site — choose another above.

  • Health Awareness, Inc. - Port St. Lucie
    Port Saint Lucie, Florida 34952, United States
    Completed

    Not enrolling at this site — choose another above.

  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
    Completed

    Not enrolling at this site — choose another above.

  • Accel Research - Decatur
    Decatur, Georgia 30030, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
    Completed

    Not enrolling at this site — choose another above.

  • Healthcare Research Network - Flossmoor IL
    Flossmoor, Illinois 604773027, United States
    Completed

    Not enrolling at this site — choose another above.

  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
    Completed

    Not enrolling at this site — choose another above.

  • Healthcare Research Network - Hazelwood MO
    Hazelwood, Missouri 63042, United States
    Completed

    Not enrolling at this site — choose another above.

  • Eximia Research - Raleigh
    Raleigh, North Carolina 27607, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research - Cleveland
    Beachwood, Ohio 44122, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research - Providence
    East Greenwich, Rhode Island 02818, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Trials of South Carolina - Berkeley - Moncks Corner
    Moncks Corner, South Carolina 29461, United States
    Completed

    Not enrolling at this site — choose another above.

  • Gadolin Research
    Beaumont, Texas 77702, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
    Completed

    Not enrolling at this site — choose another above.

  • San Antonio Clinical Trials
    San Antonio, Texas 78240, United States
    Completed

    Not enrolling at this site — choose another above.

  • AMR Norfolk
    Norfolk, Virginia 23502, United States
    Completed

    Not enrolling at this site — choose another above.

  • Centricity Research Brampton
    Brampton, Canada
    Recruiting
  • OCT Research ULC
    Kelowna, Canada
    Recruiting
  • Altasciences - Beaumont Clinic Montreal
    Montreal, Canada
    Recruiting
  • Mount Sinai Hospital - Leadership Sinai Centre for Diabetes (LSCD)
    Toronto, Canada
    Recruiting
  • Centre Hospitalier Universitaire de Clermont-Ferrand - Site Gabriel-Montpied
    Clermont-Ferrand, France
    Recruiting
  • CHU de Nîmes - Pain Assessment and Treatment Center
    Nîmes, France
    Recruiting
  • Hopital Cochin - Rheumatology
    Paris, France
    Recruiting
  • North Hospital
    Saint-Priest-en-Jarez, France
    Recruiting
  • Ruhr-Universitaet Bochum - Heart and Diabetes Center
    Bad Oeynhausen, Germany
    Recruiting
  • FutureMeds GmbH
    Berlin, Germany
    Recruiting
  • FutureMeds Frankfurt
    Offenbach/Main, Germany
    Recruiting
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, Italy
    Recruiting
  • IRCCS Ospedale San Raffaele - InSpe and Division of Neuroscience
    Milan, Italy
    Recruiting
  • Birmingham Heartlands Hospital - Heartlands Hospital Diabetes Centre and MIDRU
    Birmingham, United Kingdom
    Recruiting
  • FutureMeds Birmingham
    Birmingham, United Kingdom
    Recruiting
  • Ninewells Hospital - Endocrinology
    Dundee, United Kingdom
    Recruiting
  • FutureMeds Glasgow
    Glasgow, United Kingdom
    Recruiting
  • University of Liverpool - Aintree University Hospital
    Liverpool, United Kingdom
    Recruiting
  • St Pancras Clinical Research
    London, United Kingdom
    Recruiting
  • Manchester Diabetes Centre (MDC)
    Manchester, United Kingdom
    Recruiting
  • George Eliot Hospital NHS Trust
    Nuneaton, United Kingdom
    Recruiting
  • Royal Hallamshire Hospital - Endocrinology
    Sheffield, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 29 months is above that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 1, 2024
StartActual
Oct 18, 2024
Primary completionEst.
Mar 25, 2027
CompletionEst.
Apr 22, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06619860
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 18, 2024
Primary completion
Mar 25, 2027 (estimated)
Completion
Apr 22, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
617-341-6777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-993

Start the discussion